Research ArticleArticle
Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun, Fenglong Xie, John W. Baddley, Kevin Winthrop, Kenneth G. Saag and Jeffrey R. Curtis
The Journal of Rheumatology March 2017, jrheum.160685; DOI: https://doi.org/10.3899/jrheum.160685
Huifeng Yun
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
Fenglong Xie
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
John W. Baddley
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
Kevin Winthrop
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
Kenneth G. Saag
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
Jeffrey R. Curtis
From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. H. Yun received research support from Amgen. Dr. Baddley received research support from BMS. Dr. Winthrop received research support from Pfizer. Dr. Saag received research support from Amgen, and consulting fees from Amgen and Astra Zeneca. Dr. Curtis received research support from Amgen, Pfizer, Crescendo, Corrona, and consulting fees from Amgen, Janssen, Pfizer, and Corrona. H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, Faculty Office Towers 802D, Birmingham, Alabama 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication January 31, 2017.
Abstract
Objective The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases.
Methods Using 2006–2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression.
Results Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years.
Conclusion HZ vaccination was significantly protective only for about 5 years among patients with AI.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun, Fenglong Xie, John W. Baddley, Kevin Winthrop, Kenneth G. Saag, Jeffrey R. Curtis
The Journal of Rheumatology Mar 2017, jrheum.160685; DOI: 10.3899/jrheum.160685